Valencia Technologies Corporation
Radically small, low-cost, easy to implant neurostimulators
- Funding Goal $30,000,000
- Minimum Reservation $25,000
- Pre-money Valuation $60,361,904
- Open Date 11/03/2014
- Closing Date 05/31/2015
- Track record of success
- $20B Market
- Statistician says 70-85% projected success in FDA trial
Valencia Technologies has not only designed a tiny pacemaker, but developed and tested it for the treatment of hypertension. The technology is low cost to produce, simple to implant, and effective.
Why We Started This Company
Valencia Technologies was founded upon a plan to create tiny, low-cost neurostimulators for the treatment of major chronic conditions like hypertension.
What Sets Us Apart
Founded upon the top leadership talent of Jeff Greiner, neural engineering knowledge of Dave Peterson, and electrode and mechanical packaging expertise of Chula Thenuwara, Valencia’s team is unmatched in its mission to create low-cost neurostimulators for chronic conditions. The technology is unlike any neurostimulation device on the market. It’s 1/8th the volume of the smallest pacemaker-like device, low-cost to produce, and simple to implant.
Our Keys To Success
Valencia has done the work to design, develop, and test (in its first application) its tiny neurostimulator for the treatment of chronic conditions. Its leadership, team, and product underlie these accomplishments and will push forward for Valencia’s next steps on its path to success: a successful FDA trial and a robust sales force.
Successful internal audit for 13485 certification.
One patent issued and 18 utility patent applications pending before the USPTO.
The early clinical results show clinically significant reductions in blood pressure using the gold standard measurement.